Soldier Hard, my OPINION on LBTN is that they have made a claim to have a diagnostic tool to classify breast cancer that is, as of yet, to be verified as viable from anyone outside the company. Dr. Keith is an officer of the company. The company is a pink. Nobody in their right might takes what an officer of a pink company says as gospel, especially on a medical breakthrough, without that being verified.
"These new results are soon to appear in a major peer review medical journal."
WHEN/IF that happens, and it comes from a reputable source, LBTN should have a nice bounce. That almost 9B shares O/S will obviously keep it from bouncing as much as it would if that O/S were more reasonable, but I think it could still bounce nicely. I FULLY EXPECT the company is going to sell shares into that news, which will also affect how much of a bounce it will get. It's going to depend on the buying pressure, but I DO think that a verifiable medical substantiation of their claim WILL bounce this play. I may have to buy a lotto ticket myself.
I see by your posts that you got in at .0001. I'd guess that you have a pretty nice chance of a bagger or two from there. Biggest problem I see is that it appears they are almost fully diluted and may up the A/S or R/S it to give them more room for more dilution. THAT is what I'd be watching out for.
Good luck on it!
JJ
Tuesday, March 27 2007 12:11 PM, GMT-05:00
Lifeline Biotechnologies' Classification of Breast Cancer is No Longer a Myth but a Fact
Business Wire "US Press Releases "
RENO, Nev.--(BUSINESS WIRE)--
Lifeline Biotechnologies, Inc. (OTCPK: LBTN) today announced that its Neural Network Classification of breast cancer with blind temperature screening is no longer a myth but a fact.
According to Louis Keith, MD, PhD, Lifeline Biotechnologies, Medical Director and Vice President, "Predicting the future with Artificial Intelligence has always been a hit or miss proposition. Predictions have been made on computers whose functional capacities were limited but ever increasing. This means, in practical terms, that yesterday's predictions, however good, became out of date with the next generation of computers."
Jim Holmes, Lifeline's CEO, stated, "After almost three years of investigation, an entirely new neural network has been developed, which has become the basis of a new Lifeline patent application on thermal interpretation. Our system had been under trained. We had the correct ideas with Artificial Intelligence, but we had no idea that we had not pushed our system to its ultimate limits. Lifeline Biotechnologies is now on the right path. These new results are soon to appear in a major peer review medical journal."
About Lifeline Biotechnologies, Inc.:
Lifeline Biotechnologies, Inc. is a company with innovative medical technologies committed to the improvement of the quality of life through exceptional health care systems. These technologies focus on prevention, early detection, diagnosis and quick recovery of a number of disease conditions. The company's technologies, designed to assist in the early detection of cancers, deal with cutting-edge innovation to assist practicing physicians in the delivery of quality medical care.
SAFE HARBOR: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
Source: Lifeline Biotechnologies, Inc.
I am not a broker and profess to know nothing about trading stocks. Do your own DD. Buy, don't buy...sell, or don't sell at your own risk.
